SUPREMO Trial Shows Chest Wall Radiation May Be Omitted in Intermediate-Risk Breast Cancer Without Compromising Survival
核心洞察
The international SUPREMO trial found no significant difference in 10-year overall survival between breast cancer patients who received postmastectomy chest wall irradiation versus those who did not (81.4% vs 81.9%).
Among 1,607 women with intermediate-risk early breast cancer, chest wall recurrence occurred in only 1.1% of irradiated patients versus 2.5% of non-irradiated patients, representing less than 2 percentage points difference.
The findings suggest modern systemic therapies may provide sufficient disease control, potentially allowing radiation therapy to be omitted in certain intermediate-risk patients.
The landmark international SUPREMO trial is challenging established treatment protocols for intermediate-risk early breast cancer, demonstrating that omitting chest wall radiation after mastectomy does not compromise survival outcomes when combined with modern systemic therapies. The phase III study, published in The New England Journal of Medicine, enrolled 1,607 women and followed them for a median of 9.6 years.
Trial Design and Patient Population
The SUPREMO trial (ISRCTN61145589) recruited women with intermediate-risk breast cancer, defined as stage pT1N1, pT2N1, or pT3N0 disease, or stage pT2N0 with additional high-risk features such as histologic grade 3 or lymphovascular invasion. After mastectomy and axillary evaluation, all patients received systemic therapy and were randomized to either undergo chest wall irradiation (40-50 Gy) or receive no irradiation. The primary endpoint was overall survival assessed over 10 years.
Approximately three-quarters of the study participants were from the United Kingdom, with the remainder from other international sites. The irradiation group included 808 patients, while 799 patients were assigned to the no-irradiation group.
Survival Outcomes Show No Significant Difference
The trial's most striking finding was the virtually identical survival rates between treatment groups. Kaplan-Meier estimates showed 10-year overall survival of 81.4% in the irradiation group versus 81.9% in the no-irradiation group, with a hazard ratio for death of 1.04 (95% CI, 0.82-1.30; P=0.80).
Disease-free survival and distant metastasis-free survival were similarly comparable between groups. Ten-year disease-free survival estimates were 76.2% in the irradiation group versus 75.5% in the no-irradiation group (HR, 0.97; 95% CI, 0.79-1.18). Distant metastasis-free survival estimates were 78.2% and 79.2%, respectively (HR, 1.06; 95% CI, 0.86-1.31).
Local Recurrence Rates Remain Low
While chest wall recurrence was slightly higher in the no-irradiation group, the absolute difference remained clinically modest. Chest wall recurrence occurred in 9 patients (1.1%) who received irradiation compared to 20 patients (2.5%) who did not—an absolute difference of less than 2 percentage points (HR, 0.45; 95% CI, 0.20-0.99).
"We've now shown that with contemporary anti-cancer treatments, the risk of recurrence is very, very low—sufficiently low to avoid radiotherapy in most patients," said Ian Kunkler, MD, chief investigator of the international trial and lead author of the study.
Safety Profile Favors Omission of Radiation
The trial documented fewer treatment-related adverse events in the no-irradiation group. Lung-related adverse events of grade 2 or higher occurred in 13 patients in the irradiation group versus 5 in the no-irradiation group (odds ratio, 2.59; 95% CI, 0.97-8.12). Smaller differences in heart-related and bone-related adverse events were also observed between the groups. Notably, death from lung cancer occurred equally in both groups, with seven patients (0.9%) in each arm.
Implications for Modern Breast Cancer Care
The SUPREMO findings represent a significant shift in the therapeutic balance for intermediate-risk breast cancer patients. The results suggest that the survival advantage historically attributed to radiation therapy may be diminishing as systemic therapies become more effective. This evolution highlights the increasing potency of targeted therapies, endocrine agents, and immunomodulating regimens in preventing both local and distant recurrence.
The trial's conclusions support a more individualized approach to postmastectomy care, where clinicians can increasingly rely on systemic therapy effectiveness rather than routine radiation for local control. This paradigm shift has important implications for treatment planning, patient quality of life, and healthcare resource allocation.
As chest wall irradiation becomes less routine for certain patients, the role of pharmacists in optimizing medication regimens, managing adherence to long-term oral therapies, and addressing treatment-related toxicities becomes increasingly critical to maintaining therapeutic success.